Journal: Scientific Reports

Article Title: Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas

doi: 10.1038/s41598-026-35887-7

Figure Lengend Snippet: Mean (logRQ ± SE) expression of BIRC3 and XAF1 genes depending on PD-1 expression, The U Mann Whitney Test.

Article Snippet: The following TaqMan probes were used for the reaction: NAIP (Hs03037952_m1), BIRC2 (Hs00357350_m1), BIRC3 (Hs00154109_m1), XIAP (Hs00236913_m1), BIRC5 (Hs00153353_m1), BIRC6 (Hs00212288_m1), BIRC8 (Hs01057786), XAF1 (Hs01550138_m1), DIABLO (Hs00219876_m1), CASP3 (Hs00234387_m1) and CASP9 (Hs00962278_m1).

Techniques: Expressing, MANN-WHITNEY

Journal: Current Oncology

Article Title: Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan–Brazilian Border

doi: 10.3390/curroncol32060333

Figure Lengend Snippet: Paraguay area description for TP53 p.R337H variant and XAF1 p.E134* variant screening 1 . 1 Paraguay (area inside rectangle) is subdivided into 17 departments (provinces or states). Blood samples from newborns screened for TP53 p.R337H variant were collected from towns located in Departments 2, 3, 4, 5, 6, 8, 9, 11, 12, 15, 16, and 17 (colored in dark and light green). Blood samples from newborns screened for XAF1 p.E134* were collected from towns located in Departments 3, 8, 9, 11, and 15 (colored in dark green). No blood samples were collected from towns located in Departments 1, 7, 10, 13, and 14 (colored in yellow) at the border with Brazil, which received most Brazilian immigrants in the past. This area was previously screened for TP53 p.R337H variant in .

Article Snippet: The prevalence of the germline variant XAF1 p.E134* in Paraguay was also compared with a database from NCBI—National Center for Biotechnology Information [ ]—which includes samples from countries in Latin America and Europe.

Techniques: Variant Assay

Journal: Journal of translational medicine

Article Title: Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment.

doi: 10.1186/s12967-025-06455-w

Figure Lengend Snippet: Fig. 4 RNA sequencing of A2058 cells to investigate the function of CLSPN. (A) Volcano plot of the differential gene expression between CLSPN knock down group and the control group. The red points represented significantly up-regulated gene, and the blue points represented significantly down-reg ulated gene. (B) The top 20 enrichment of KEGG pathway terms analysis for the differential genes.(C) Protein-protein interaction analysis of differentially expressed functional genes. (D) Molecular docking result of CLSPN/IFI44L. (E) The mRNA expression of IFI44L and downstream genes after CLSPN knock down in A2058 by qPCR. (F) The protein levels of CLSPN, IFI44L, p-STAT1, STAT1 and XAF1 after si-CLSPN transfection by western blot. (G) The quantifica tion results of western blot by Image J (n = 3). Data were expressed as mean ± SD. * p < 0.05 and ** p < 0.01

Article Snippet: The membranes were blocked using 5% non-fat milk for 1 h, incubated overnight with primary antibodies against CLSPN (Affinity, DF7525), IFI44L (SAB, 27948), p-STAT1 (Proteintech, 28977-1-AP), STAT1 (Proteintech, 10144-2-AP), XAF1 (BOSTER, BA4986), GAPDH (Affinity, AF7021), antiBax (Cell Signaling Technology, #5023), anti-Bcl-2 (Cell Signaling Technology, #3498), anti-cleaved-PARP (Cell Signaling Technology, #5625T), anti-cleaved-caspase 9 (Cell Signaling Technology, #20750), anti-β-tubulin (Affinity, AF7011), anti-β-actin (Affinity, #AF7018) at 4 °C, and then incubated for 1 h with secondary antibody goat Anti-Rabbit IgG (Affinity, #S0001).

Techniques: RNA Sequencing, Gene Expression, Knockdown, Control, Functional Assay, Expressing, Transfection, Western Blot